Navigation Links
InteKrin Therapeutics Announces Enrollment Completion of 360 Patient, 24 week Phase 2b Study
Date:3/11/2009

LOS ALTOS, Calif., March 11 /PRNewswire/ -- InteKrin Therapeutics, Inc., a clinical stage biopharmaceutical company focused on diabetes, metabolism and obesity, today announced it has completed enrollment of a 360 patient Phase 2b study of INT131, a novel, non-TZD selective modulator of PPAR gamma (SPPARM) for the treatment of Type 2 diabetes (T2DM). INT131-007 is a 24 week, high dose active comparator (45mg Actos(R)) and placebo controlled study of INT131 at four doses in poorly controlled Type 2 diabetics.

"INT131-007 is an important study designed specifically to extend the encouraging findings from our Phase 2a study and demonstrate the unique properties of INT131, a potent insulin sensitizer, in patients with inadequately controlled type 2 diabetes mellitus (T2DM), said Alex DePaoli, M.D. InteKrin's Chief Medical Officer. "This Phase 2b study will provide critical efficacy, safety, and tolerability data to allow differentiation of INT131 from Actos(R) and inform dose selection for the Phase 3 program".

"InteKrin is very pleased to achieve this critical development milestone for INT131," remarked InteKrin's President and CEO, Denny Lanfear. "We anticipate having results from INT131-007 in the second half of this year concurrent with completion of all nonclinical and CMC efforts, enabling initiation of the INT131 Phase 3 program in 1H2010."

INT131 is a selective PPAR gamma modulator which has consistently demonstrated the separation of the powerful PPAR gamma anti-diabetic efficacy from the well recognized TZD side effects. INT131 is well positioned to fulfill the unmet medical need for patients requiring safe treatment of insulin resistance, a key etiological feature in the onset and subsequent progression of T2DM, which remains inadequately addressed by current therapies.

About InteKrin (www.InteKrin.com):

InteKrin Therapeu
'/>"/>

SOURCE InteKrin Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... LONDON , Sept. 2, 2015 ... Forecasts Summary Advanced dressings have steadily ... treatment of a variety of wound indications, such ... fluid management, infection control, and physical protection become ... a greater role in standard therapy. This ...
(Date:9/2/2015)... , Sept. 2, 2015 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye, today announced ... Wall to the Company,s Board. Mr. ... Boston -based investment firm, for more than ... Board of Directors, and chair of the Corporate Governance Committee ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/hcb7bz/pharmaceutical ) has announced ... UK - November 16-18, 2015)" conference to their offering. ... including Columbia, Peru , Brazil ... Uruguay , Paraguay , Venezuela ... , Chile This seminar can be ...
Breaking Medicine Technology:Advanced Wound Dressings - 5EU Analysis and Market Forecasts 2William P. Wall Appointed to STAAR Surgical Board of Directors 2Pharmaceutical Regulatory Affairs in Latin America Seminar - London, UK - November 16-18, 2015 2
... NetMotion Wireless, a leading provider of mobile productivity ... mobile Virtual Private Network (VPN) solution, Mobility XE, has ... hundreds of mobile workers for accessing wireless data and ... advance medical care, improve staff productivity and increase practice ...
... Sept. 7 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) ... conferences in September: Morgan Stanley Global Healthcare Conference ... York Stifel Nicolaus 2010 Healthcare ConferenceWednesday, September 15, at ... Conference Tuesday, September 21, at 9:00 a.m. ET in ...
Cached Medicine Technology:NetMotion Wireless Tapped by IDEXX Laboratories to Provide Secure Mobile Access to Field Personnel 2NetMotion Wireless Tapped by IDEXX Laboratories to Provide Secure Mobile Access to Field Personnel 3MAP Pharmaceuticals to Present at Upcoming Healthcare and Scientific Conferences 2
(Date:9/2/2015)... DC (PRWEB) , ... September 03, 2015 , ... ... of nominations to determine who among America’s policymakers, public servants, activists, corporate executives, ... the nation’s health care. This year, that process led the magazine to tap ...
(Date:9/2/2015)... ... 02, 2015 , ... Chris Harrison of Harrison’s Footwear of Poulsbo announces the ... really,” says Chris. “We have a lot of repeat customers, and many of them ... for them—so we’ve given them the convenience of ordering from home.” , Harrison’s Footwear ...
(Date:9/2/2015)... ... 02, 2015 , ... Healthegy, a leading producer of conferences, ... will deliver keynote presentations at the upcoming Digital Healthcare Innovation Summit ( http://www.digitalhealthcaresummit.com/ ... , Larry Renfro, CEO of Optum, will deliver the morning address. In his ...
(Date:9/2/2015)... Los Angeles, CA (PRWEB) , ... September 02, 2015 , ... ... working to expand their fleet of truly superb luxury vehicles based on which of ... are pleased to announce the latest step forward in pursuit of this goal: a ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham and Mildred ... comes six months after WCHN recruited nationally known gynecologic oncologist Thomas J. Rutherford, ...
Breaking Medicine News(10 mins):Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 2Health News:NLN CEO Dr. Beverly Malone Named One of 100 Most Influential in Health Care 3Health News:Harrison's Comfort Footwear Announces Expansion with New CHarrison Online Store 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 2Health News:Larry Renfro, CEO of Optum and Jonathan Bush, CEO of AthenaHealth to Address Healthcare Entrepreneurs and Investors at 5th Annual Digital Healthcare Innovation Summit 3Health News:Luxury Line Auto Rental Announces Addition of the Rolls Royce Wraith to their Luxury Fleet 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3
... is helping to increase understanding about normal vaginal biology ... women prone to infections and other diseases, and ... suffer from insidious health problems, including bacterial vaginosis and ... to seek medical treatment, said Larry Forney, a professor ...
... times as much food as conventional farming on the ... refute the long-standing assumption that organic farming methods cannot ... ,Researchers from the University of Michigan found that ... and conventional farms. In developing countries, food production could ...
... found that children with Tourettes syndromean inherited neurological disorder ... learn certain mental grammar skills much faster than their ... at Georgetown University Medical Center and the Kennedy Krieger ... linked to tics in Tourettes syndrome may also result ...
... of Havana have found that two compounds from lobster ... properties. ,The researchers said that the compounds could ... and antiseptic properties, as well as to increase growth ... a very common polymer present in nature as part ...
... Laboratories announced primary results for its large-scale clinical ... non-hormonal, non-prescription Zestra(R) Feminine Arousal Fluid for ... study, designed and managed by David M. Ferguson, ... parallel design trial intended to expand on the ...
... day, the Australian police finally announced that the Dr.Mohammed ... charged with providing reckless support to terrorists by ... ,His cousin Sabeel Ahmed 26, who worked at Halton ... of having information that could have helped police prevent ...
Cached Medicine News:Health News:Vaginal Bacteria Vary Among Healthy Women 2Health News:Organic Farming Can Feed the World 2Health News:Organic Farming Can Feed the World 3Health News:Tourettes Syndrome in Children may also Result in Superior Learning Skills 2Health News:Lobster Shells Have Great Healing and Antiseptic Properties 2Health News:Study Shows Positive Results for Zestra(R) Feminine Arousal Fluid 2Health News:Three Doctors Charged So Far in the UK Bombing Case 2Health News:Three Doctors Charged So Far in the UK Bombing Case 3Health News:Three Doctors Charged So Far in the UK Bombing Case 4
... flexible lighting products. The first is available ... sizes 5", 10", and 15" (refers to ... These lights are for use in procedures ... second group of flexible lights is our ...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
These units, though small, still offer sufficient output to ensure current is fully adjustable from 0 to 70 mA. Instruction manual, ball electrodes, battery and leads with alligator clips are include...
... standby switch maintains power to the instrument without generating ... of 50 Hz separated by .75 s; repeats every ... Hz (2 pulses/s) , Tetanus: 50 Hz (50 ... pulses/2 s; repeats every 10 s , Output Current: ...
Medicine Products: